Loading
A phase 2 trial of High-dose intravenous vitamin C in Rectal cancer, run by Sixth Affiliated Hospital, Sun Yat-sen University, not yet recruiting.
NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARC is a phase 2 interventional study registered as NCT07765667 by Sixth Affiliated Hospital, Sun Yat-sen University, with 100 participants planned, started 2026-09-01 and due to reach its primary completion in 2029-09-01. Interventions recorded: Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen, Ketogenic Diet, Surgical resection, Vitamin C. Conditions recorded: Rectal Adenocarcinoma, High-Risk Cancer, MSS.
Linked to the technology High-dose intravenous vitamin C because the registry's title names it ("high dose intravenous vitamin c") and Rectal cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares High-dose intravenous vitamin C, Rectal cancer and the tag pipeline.
Shares High-dose intravenous vitamin C and the tag pipeline.
Shares Rectal cancer and the tag pipeline.
Shares Rectal cancer and the tag pipeline.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin) and the tag pipeline.
Shares Rectal cancer and the tag pipeline.
Shares Rectal cancer and the tag pipeline.
Shares Rectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/